The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates in different stages of development.
The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer.
It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity.
Browse the Report Summary at: www.psmarketresearch.com/market-an…ipeline-analysis
CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell.
The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.
The research finds that the different companies are collaborating for the development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and Juno Therapeutics, Inc.
collaborated for the development and commercialization of immunotherapies.
Explore Report Sample at: www.psmarketresearch.com/market-an…sis/report-sample
Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc. and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: